EVFM Stock Forecast 2024-2030
Article Coverage: EVFM Performance, EVFM Prediction Analysis, EVFM Stock Forecast 2024-2030, About Evofem Biosciences and Earnings.
EVFM Stock: Latest Price
| Metric | Value | Trend |
|---|---|---|
| Current Price | $0.0128 | Steady |
| Trading Volume | $1.9 M | Lower |
EVFM Stock Performance so far
| Last 5 Days | -28.6% |
| Last 1 Month | -25.0% |
| Last 12 Months | -99.4% |
EVFM stock price has been in a free fall over the last few days. What are the predictions and signals?
| Overall Outlook | Partially Bullish |
| 1. Market's Wisdom | Partially Bullish |
| 1a. Market Data | Neutral |
| 1b. Technical Recommendation | Buy |
| 2. Crowd's Wisdom | Neutral |
| 2a. Social Media Buzz | Steady |
| 2b. Social Media Sentiment | Steady |
EVFM stock has further crashed and now the stock is under the pressure of crashing below $0.010. For EVFM $0.015 is the immediate support and if stock price fails to hold above this level, the likelihood of EVFM crashing below $0.010 will increase exponentially. Recently EVFM was rejected just below $0.030 and the price has been on a downtrend since then.
Technically EVFM is highly bearish and the trade recommendation for the asset is sell.
EVFM Stock Price Prediction for the next 12 months
| Average EVFM Stock Forecast for the next 12 Months | $1.81 |
| Stifel | $0.5 |
| HC Wainwright & Co. | $4 |
| Piper Sandler | $2 |
| Morgan Stanley | $0.75 |
EVFM Stock Forecast 2024-2030
- EVFM Evofem Stock Price Prediction 2024 is $0.0259
- EVFM Evofem Stock Price Prediction 2025 is $0.0349
- EVFM Evofem Stock Price Prediction 2026 is $0.0449
- EVFM Evofem Stock Price Prediction 2027 is $0.0589
- EVFM Evofem Stock Price Prediction 2028 is $0.0739
- EVFM Evofem Stock Price Prediction 2029 is $0.0939
- EVFM Evofem Stock Price Prediction 2030 is $0.117
Evofem Biosciences Earnings
Latest Earnings
Evofem Biosciences reported results for Q4 2023 on March 27, 2024. Here are some key highlights:
- Revenue: $4.84 million
- Net loss: $2.11 million, which is an improvement compared to a net loss of $8.34 million in Q4 2022
- Phexxi net product sales: $18.2 million for the entire year 2023
- Sales and marketing expenses: Showed significant improvement as a percentage of net sales
Previous 4 Earnings
| Sept 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
| Revenue | 51.12L | 24.58L | 58.09L | 1.81L |
| Net income | 6.6Cr | -85.58L | -23.54L | -83.36L |
| Diluted EPS | 0.1 | – | – | -12.89 |
| Net profit margin | 1291.18% | -348.17% | -40.52% | -4605.52% |
| Operating income | -35.52L | -73.36L | -35.79L | -1.21Cr |
| Net change in cash | -2.26L | -8.98L | -32.42L | -50.66L |
| Cost of revenue | 18.89L | 22.93L | 13.76L | 3.84L |
EVFM Stock Forecast 2024: About Evofem Biosciences
Evofem Biosciences is a commercial-stage biopharmaceutical company focused on women’s sexual and reproductive health. Evofem Biosciences was founded in 2007 and is headquartered in California.
The mission of Evofem Biosciences is to develop innovative products that address unmet needs in women’s healthcare, with a focus on hormone-free contraception and protection against certain sexually transmitted infections (STIs).
What is the key product of Evofem Biosciences?
The key product of Evofem Biosciences is Phexxi, a first-in-class hormone-free, on-demand prescription contraceptive vaginal gel.
EVFM Stock Forecast 2024: About EVFM Stock
EVFM stock was delisted from NASDAQ exchange and now it has been listed on the OTC exchange. The stock has been struggling to find enough buyers. Before the coronavirus pandemic, the stock was traded in a range of $100 and is now left in shambles.
EVFM’s product is a contraception gel for women. And their selling vantage point is that it is hormone-free, unlike other oral protections that cause mood swings, depression, etc. However, in recent trials, it was proved that it is not as safe as conventional protection applicators. In the trial, around 1900 women tested positive for STI. This reason alone may have affected the stock price adversely. However, it is FDA approved birth control vaginal gel applicator. And its market value of $6.8 million with a price-to-sales ratio is coming down as cheap as 1.9x. If the company can optimize its operating expenses, it can become profitable and provide high rewards to the investors.
Note: Crowdwisdom360 collates Predictions and data from all over the net and has no in-house view on the likely trends in the Stocks or Crypto Coins. Please consult a registered investment advisor to guide you on your financial decisions